Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander?

Jay W Heinecke, Jay W Heinecke

Abstract

Oxidation of low-density lipoprotein (LDL) is thought to contribute to atherosclerosis and cardiovascular disease. Consistent with this idea, the antioxidant drug probucol reduces the risk of restenosis, a form of cardiovascular disease, in humans. However, a new study now suggests that the protective effect of probucol depends not on its ability to inhibit lipid oxidation, but on its ability to induce the stress-induced antiinflammatory enzyme heme oxygenase (HO)-1. This might explain why other antioxidants, such as vitamin E, fail to prevent cardiovascular disease in humans.

Figures

Figure 1.
Figure 1.
Initiation and progression of atherosclerotic lesions. LDL enters the subendothelial space and is oxidized. Oxidized LDL (OxLDL) promotes monocyte adhesion to injured or inflamed epithelium and migration into the artery wall, where the cells differentiate into macrophages. OxLDL also binds to scavenger receptors on macrophages. This binding triggers uptake of OxLDL, converting macrophages into lipid-laden foam cells. Subsequently, smooth muscle cells migrate into the subendothelial space, where they accumulate and produce extracellular matrix, two important components of more advanced atherosclerotic lesions.
Figure 2.
Figure 2.
Proposed pathways for the impact of probucol on the pathogenesis of vascular disease. (A) LDL in the intima of the artery wall is oxidized with the generation of proatherogenic lipid oxidation products (OxLDL). The phenol moiety of probucol blocks this process by acting as a scavenger of one-electron oxidants. (B) Vascular injury results in endothelial injury, smooth muscle cell (SMC) proliferation, and an influx of inflammatory cells and SMCs into the intima. Probucol induces the cellular expression of HO-1, presumably by cells of the artery wall. HO-1 reduces intimal hyperplasia and promotes tissue repair by several direct cellular actions. For example, the HO-1 product CO has been shown to inhibit endothelial cell (EC) apoptosis, prevent SMC proliferation, and inhibit macrophage production of inflammatory mediators, all of which may be important in vascular protection. Probucol may also react with two-electron oxidants that play a role in tissue injury.

References

    1. Witztum, J.L., and D. Steinberg. 1991. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1785–1792.
    1. Heinecke, J.W. 1998. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 141:1–15.
    1. Heinecke, J.W., H. Rosen, and A. Chait. 1984. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J. Clin. Invest. 74:1890–1894.
    1. Morel, D.W., P.E. DiCorleto, and G.M. Chisolm. 1984. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 4:357–364.
    1. Steinbrecher, U.P., S. Parthasarathy, D.S. Leake, J.L. Witztum, and D. Steinberg. 1984. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA. 81:3883–3887.
    1. Haberland, M.E., L. Cheng, and D. Fong. 1988. Malondialdehyde-altered protein occurs in atheroma of Watanabe Heritable hyperlipidemic rabbits. Science. 241:215–217.
    1. Rosenfeld, M.E., W. Palinski, S. Yla-Herttuala, S. Butler, and J.L. Witztum. 1990. Distribution of oxidation specific lipid-protein adducts and apolipoprotein-B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10:336–346.
    1. Kita, T., Y. Nagano, M. Yokode, K. Ishi, N. Kume, A. Ooshima, H. Yoshida, and C. Kawai. 1987. Probucol prevents the progression of atherosclerosis in Watanabe Heritable Hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84:5928–5932.
    1. Carew, T.E., D.C. Schwenke, and D. Steinberg. 1987. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe Heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. USA. 84:7725–7729.
    1. Parthasarathy, S., S.G. Young, J.L. Witztum, R.C. Pittman, and D. Steinberg. 1986. Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. 77:641–644.
    1. Wu, B.J., K. Kathir, P.K. Witting, K. Beck, K. Choy, C. Li1, K.D. Croft, T.A. Mori, D. Tanous, M.R. Adams, et al. 2006. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J. Exp. Med. 203:1117–1127.
    1. Stephens, N.G., A. Parsons, P.M. Schofield, F. Kelly, K. Cheeseman, and M.J. Mitchinson. 1996. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:781–786.
    1. 1999. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 354:447–455.
    1. Yusuf, S., G. Dagenais, J. Pogue, J. Bosch, and P. Sleight. 2000. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:154–160.
    1. Lee, I.M., N.R. Cook, J.M. Gaziano, D. Gordon, P.M. Ridker, J.E. Manson, C.H. Hennekens, and J.E. Buring. 2005. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 294:56–65.
    1. Bergt, C., S. Pennathur, X. Fu, J. Byun, K. O'Brien, T.O. McDonald, P. Singh, G.M. Anantharamaiah, A. Chait, J. Brunzell, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA. 10:13032–130327.
    1. Zheng, L., B. Nukuna, M.L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt, X. Fu, L. Thomson, P.L. Fox, et al. 2004. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114:529–541.
    1. Otterbein, L.E., M.P. Soares, K. Yamashita, and F.H. Bach. 2003. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 24:449–455.
    1. Deng, Y.M., B.J. Wu, P.K. Witting, and R. Stocker. Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase- 1. Circulation. 110:1855–1860.
    1. Tardif, J.C., G. Cote, J. Lesperance, M. Bourassa, J. Lambert, S. Doucet, L. Bilodeau, S. Nattel, and P. de Guise. 1997. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N. Engl. J. Med. 337:365–372.
    1. Tardif, J.C., J. Gregoire, L. Schwartz, L. Title, L. Laramee, F. Reeves, J. Lesperance, M.G. Bourassa, P.L. L'Allier, M. Glass, et al; Canadian Antioxidant Restenosis Trial. 2003. (CART-1) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation. 107:552–558.
    1. Sawayama, Y., C. Shimizu, N. Maeda, M. Tatsukawa, N. Kinukawa, S. Koyanagi, S. Kashiwagi, and J. Hayashi. 2002. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J. Am. Coll. Cardiol. 39:610–616.
    1. Tardif, J.C. 2003. Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am. J. Cardiol. 91(3A):41A–49A.
    1. Daugherty, A., J.L. Dunn, D.L. Rateri, and J.W. Heinecke. 1994. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94:437–444.
    1. Hazell, L.J., L. Arnold, D. Flowers, G. Waeg, E. Malle, and R. Stocker. 1996. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest. 97:1535–1544.
    1. Hazen, S.L., and J.W. Heinecke. 1997. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99:2075–2081.
    1. Brennan, M.L., M.M. Anderson, D.M. Shih, X.D. Qu, X. Wang, A.C. Mehta, L.L. Lim, W. Shi, S.L. Hazen, J.S. Jacob, et al. 2001. Increased atherosclerosis in myeloperoxidase-deficient mice. J. Clin. Invest. 107:419–430.
    1. Hazell, L.J., and R. Stocker. 1997. Alpha-tocopherol does not inhibit hypochlorite- induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEBS Lett. 414:541–544.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner